House of Lords Business
Show full summary

Lord Mendelsohn to ask His Majesty's Government why the Medicines and Healthcare products Regulatory Agency claimed in their 6 September letter to Gemma Peters, Chief Executive of Blood Cancer UK, that there is ongoing uncertainty about whether the results from the PROVENT study on Evusheld shed light on clinical effectiveness, given this study supported their decision to approve single and double doses of Evusheld in the UK in March.  HL2599

Question HL2599: tabled on 13 October 2022 and due for answer by 27 October 2022

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Mendelsohn to ask His Majesty's Government why the Medicines and Healthcare products Regulatory Agency claimed in their 6 September letter to Gemma Peters, Chief Executive of Blood Cancer UK, that there is ongoing uncertainty about whether the results from the PROVENT study on Evusheld shed light on clinical effectiveness, given this study supported their decision to approve single and double doses of Evusheld in the UK in March.  HL2599
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Lord Mendelsohn
Labour
Life peer